Personalized cancer therapy for gastrointestinal stromal tumor: Synergizing tumor genotyping with imatinib plasma levels

Andrea Marrari, Jonathan Trent, Suzanne George

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Imatinib has exceptional activity in controlling gastrointestinal stromal tumor (GIST) due to inhibition of the constitutively active conformation of KIT and platelet-derived growth factor-alpha (PDGFRA), which is commonly seen in this tumor. This review explores the current available data on the correlation between imatinib plasma levels, response to treatment, and the mutational status of KIT and PDGFRA. RECENT FINDINGS: A recent retrospective analysis demonstrated a relationship between imatinib plasma levels and progression-free survival in patients with advanced GIST. Plasma imatinib levels were notably unrelated to the daily administered dose of imatinib in this small series. Prior phase III trials have demonstrated that dose escalation of imatinib may lead to increased disease control in a subset of patients with advanced GIST who progress on standard dose imatinib. Moreover, patients with GIST carrying an exon 9 mutation may benefit from higher doses of imatinib. SUMMARY: Current available data suggest a possible correlation between imatinib plasma level and progression-free survival in patients with advanced GIST. A prospective trial is underway to evaluate whether modification of imatinib dose to achieve a target imatinib plasma level will impact patient outcome when compared with standard imatinib dosing (www.clinicaltrials.gov, NCT01031628).

Original languageEnglish
Pages (from-to)336-341
Number of pages6
JournalCurrent Opinion in Oncology
Volume22
Issue number4
DOIs
StatePublished - Jul 1 2010
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Therapeutics
Platelet-Derived Growth Factor
Disease-Free Survival
Imatinib Mesylate
Exons

Keywords

  • gastrointestinal stromal tumor
  • imatinib plasma levels
  • tumor genotyping

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Personalized cancer therapy for gastrointestinal stromal tumor : Synergizing tumor genotyping with imatinib plasma levels. / Marrari, Andrea; Trent, Jonathan; George, Suzanne.

In: Current Opinion in Oncology, Vol. 22, No. 4, 01.07.2010, p. 336-341.

Research output: Contribution to journalArticle

@article{87e384f71afb4e88abaf2e7064f23f8f,
title = "Personalized cancer therapy for gastrointestinal stromal tumor: Synergizing tumor genotyping with imatinib plasma levels",
abstract = "Lippincott Williams &Wilkins.",
keywords = "gastrointestinal stromal tumor, imatinib plasma levels, tumor genotyping",
author = "Andrea Marrari and Jonathan Trent and Suzanne George",
year = "2010",
month = "7",
day = "1",
doi = "10.1097/CCO.0b013e32833a6b8e",
language = "English",
volume = "22",
pages = "336--341",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Personalized cancer therapy for gastrointestinal stromal tumor

T2 - Synergizing tumor genotyping with imatinib plasma levels

AU - Marrari, Andrea

AU - Trent, Jonathan

AU - George, Suzanne

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Lippincott Williams &Wilkins.

AB - Lippincott Williams &Wilkins.

KW - gastrointestinal stromal tumor

KW - imatinib plasma levels

KW - tumor genotyping

UR - http://www.scopus.com/inward/record.url?scp=77953913171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953913171&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32833a6b8e

DO - 10.1097/CCO.0b013e32833a6b8e

M3 - Article

C2 - 20489620

AN - SCOPUS:77953913171

VL - 22

SP - 336

EP - 341

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -